Research partner marketplaceCode PEPTIDESDE
PeptideStat
Index
Research noteglp-1

Zepbound vs Wegovy: Tirzepatide vs Semaglutide for Weight Loss

Zepbound vs Wegovy compared: active ingredient, average weight loss, head-to-head trial data, indications, side effects, cost and which brand fits which use case.

Published
May 18, 2026
Last reviewed
May 18, 2026
Reading time
4 min read
By
PeptideStat Editorial Team
This article separates published evidence from commercial claims. It is educational, not medical advice.

Zepbound and Wegovy are the two major branded weight-loss injections people compare. Zepbound contains tirzepatide. Wegovy contains semaglutide.

The short answer: Zepbound generally wins on average weight loss. Wegovy still has important label strengths, including cardiovascular risk-reduction use in a defined population, and it may be the better practical option when coverage or tolerability favors semaglutide.

For ingredient-level detail, read semaglutide vs tirzepatide.

Quick Comparison

QuestionZepboundWegovy
Active ingredientTirzepatideSemaglutide
MechanismDual GIP / GLP-1 receptor agonistGLP-1 receptor agonist
Weight-loss labelChronic weight managementChronic weight management
Average weight-loss edgeUsually higherStrong, but lower than Zepbound in head-to-head data
Other label strengthsIncludes obstructive sleep apnea in adults with obesityIncludes cardiovascular risk reduction in adults with overweight or obesity and established CVD

Head-to-Head Weight Loss

SURMOUNT-5 is the key study because it directly compared tirzepatide with semaglutide in adults with obesity or overweight.

Trial pointZepbound / tirzepatideWegovy / semaglutideMeaning
SURMOUNT-5 average weight lossAbout 20.2%About 13.7%Zepbound had the clear average advantage.
Mechanism explanationTwo incretin pathways: GIP and GLP-1One incretin pathway: GLP-1The extra GIP activity may help explain larger average results.
Individual responseCan still vary widelyCan still work very well for many peopleTrial averages are not personal guarantees.

Safety and Side Effects

Both products commonly cause gastrointestinal side effects, especially during dose escalation:

  • Nausea.
  • Vomiting.
  • Diarrhea.
  • Constipation.
  • Reflux or abdominal discomfort.
  • Lower appetite than intended.

Both labels also include warnings that require clinician screening. Read the product label and GLP-1 side effects before turning an efficacy comparison into a medication choice.

Which One Fits Which Search?

ScenarioOften points towardReason
Maximum average weight lossZepboundHead-to-head data favor tirzepatide.
Established cardiovascular disease plus overweight or obesityWegovyWegovy has a cardiovascular risk-reduction label in this setting.
Obstructive sleep apnea with obesityZepboundZepbound has an OSA-related obesity label.
Insurance covers one but not the otherThe covered productAccess often beats theoretical ranking.
One product causes intolerable GI effectsTry clinician-guided titration or switchingThe best drug on paper is not useful if it cannot be tolerated.

Bottom Line

Zepbound is usually the stronger weight-loss choice on average. Wegovy remains a major option because semaglutide has broad clinical data, specific label strengths and sometimes better access. The best answer is the one a prescriber can match to the patient's risk profile, indication and coverage.

FAQ

Is Zepbound better than Wegovy?

For average weight loss, Zepbound generally performs better. Wegovy may still be preferred for specific label indications, coverage or tolerability.

What is the active ingredient in Zepbound?

Zepbound contains tirzepatide, a dual GIP/GLP-1 receptor agonist.

What is the active ingredient in Wegovy?

Wegovy contains semaglutide, a GLP-1 receptor agonist.

Did Zepbound and Wegovy have a head-to-head trial?

Yes. SURMOUNT-5 directly compared tirzepatide with semaglutide in adults with obesity or overweight and found greater average weight loss with tirzepatide.

Can you switch from Wegovy to Zepbound?

People do switch, but the transition should be managed by a prescriber because doses are not equivalent and GI side effects matter.

References

  1. Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine.

  2. Eli Lilly. Zepbound prescribing information.

  3. Novo Nordisk. Wegovy prescribing information.

  4. FDA. FDA approval announcement for Zepbound in chronic weight management.

Filed under

zepbound vs wegovyzepboundwegovytirzepatidesemaglutideglp-1 comparison

Continue in the database

Structured status, mechanism and evidence notes for compounds connected to this guide.

Semaglutide

Ozempic, Wegovy, Rybelsus

5/5
Weight lossApproved

Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.

DetailsGuide

Tirzepatide

LY3298176, Mounjaro, Zepbound

5/5
Weight lossApproved

Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.

DetailsGuide

Dulaglutide

Trulicity

5/5
Weight lossApproved

Dulaglutide is a long-acting GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite.

DetailsGuide

Exenatide

Byetta, Bydureon, exendin-4

5/5
Weight lossApproved

Exenatide activates the GLP-1 receptor to increase glucose-dependent insulin secretion, suppress inappropriate glucagon release, and slow gastric emptying.

DetailsGuide

Liraglutide

Victoza, Saxenda

5/5
Weight lossApproved

Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.

DetailsGuide

Work with the numbers

Open reconstitution, unit-conversion and accumulation tools with editable examples.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open toolPeptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open toolPeptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open toolPeptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Prefilled calculator shortcuts

Open calculators with editable examples for compounds mentioned around this guide.

Semaglutide reconstitution calculatorPrefills a 5 mg vial, 2 mL BAC water and editable dose fields.Open prefilled toolSemaglutide accumulation calculatorPrefills 168 hour half-life and 168 hour interval examples.Open prefilled toolSemaglutide unit converterPrefills 250 mcg with a 5 mg vial example.Open prefilled toolTirzepatide reconstitution calculatorPrefills a 10 mg vial, 2 mL BAC water and editable dose fields.Open prefilled toolTirzepatide accumulation calculatorPrefills 120 hour half-life and 168 hour interval examples.Open prefilled toolTirzepatide unit converterPrefills 2.5 mg with a 10 mg vial example.Open prefilled tool

Explore the wider category

Compare the broader evidence landscape before focusing on one compound.

Weight Loss Peptides

Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.

Read next

GLP-1 Pancreatitis Risk: What Labels, Trials and Symptoms ShowGLP-1 pancreatitis risk is real enough to appear in labels, but rare enough that trials and meta-analyses need careful interpretation.Ozempic Vision Loss and NAION: What Semaglutide Evidence ShowsSemaglutide and NAION is now a real pharmacovigilance topic, but the absolute risk appears low and the evidence is mostly observational.Orforglipron (Foundayo): Oral GLP-1 Pill Evidence, Label and LimitsOrforglipron is the oral small-molecule GLP-1 sold as Foundayo. It is not a peptide, but it matters for peptide readers because it changes the oral GLP-1 comparison.